PRRT2 and brain injury: Therefore, finding non-tumorigenic activators of each specific PKC isozyme, which facilitate adjustment of the homeostatic balances of PKC activity, will definitely lead to the development of new drugs and therapeutic strategies to regenerate brain injuries.